MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04734nam a22005777a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
210310s20212021 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0735-1097 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1016/j.jacc.2020.12.047 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
S0735-1097(20)38265-6 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
33632476 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. |
| 251 ## - Source |
|---|
| Source |
Journal of the American College of Cardiology. 77(8):1029-1040, 2021 03 02. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
J Am Coll Cardiol. 77(8):1029-1040, 2021 03 02. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
J Am Coll Cardiol. 77(8):1029-1040, 2021 03 02. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
J Am Coll Cardiol. 77(8):1029-1040, 2021 Mar 02. |
| 253 ## - Journal Name |
|---|
| Journal name |
Journal of the American College of Cardiology |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2021 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2021 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
ppublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2021-03-10 |
| 268 ## - Previous citation |
|---|
| -- |
Journal of the American College of Cardiology. 77(8):1029-1040, 2021 03 02. |
| 268 ## - Previous citation |
|---|
| -- |
Journal of the American College of Cardiology. 77(8):1029-1040, 2021 Mar 02. |
| 269 ## - Original dates |
|---|
| Original fiscal year |
FY2021 |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
BACKGROUND: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) resulted in fewer heart failure hospitalizations (HFHs) and lower mortality at 24 months in patients with heart failure (HF) with mitral regurgitation (MR) secondary to left ventricular dysfunction compared with guideline-directed medical therapy (GDMT) alone. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: Among patients with HF and moderate-to-severe or severe secondary MR who remained symptomatic despite GDMT, TMVr was safe, provided a durable reduction in MR, reduced the rate of HFH, and improved survival, quality of life, and functional capacity compared with GDMT alone through 36 months. Surviving patients who crossed over to device treatment had a prognosis comparable to those originally assigned to transcatheter therapy. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation [COAPT]; NCT01626079). Copyright (c) 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: This study randomized 614 patients with HF with moderate-to-severe or severe secondary MR, who remained symptomatic despite maximally tolerated GDMT, to TMVr plus GDMT versus GDMT alone. The primary effectiveness endpoint was all HFHs through 24-month follow-up. Patients have now been followed for 36 months. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
OBJECTIVES: This study determined if these benefits persisted to 36 months and if control subjects who were allowed to cross over at 24 months derived similar benefit. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: The annualized rates of HFHs per patient-year were 35.5% with TMVr and 68.8% with GDMT alone (hazard ratio [HR]: 0.49; 95% confidence interval [CI]: 0.37 to 0.63; p < 0.001; number needed to treat (NNT) = 3.0; 95% CI: 2.4 to 4.0). Mortality occurred in 42.8% of the device group versus 55.5% of control group (HR: 0.67; 95% CI: 0.52 to 0.85; p = 0.001; NNT = 7.9; 95% CI: 4.6 to 26.1). Patients who underwent TMVr also had sustained 3-year improvements in MR severity, quality-of-life measures, and functional capacity. Among 58 patients assigned to GDMT alone who crossed over and were treated with TMVr, the subsequent composite rate of mortality or HFH was reduced compared with those who continued on GDMT alone (adjusted HR: 0.43; 95% CI: 0.24 to 0.78; p = 0.006). |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Heart Failure/mo [Mortality] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Heart Failure/th [Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Mitral Valve Insufficiency/su [Surgery] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Mitral Valve/su [Surgery] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cardiotonic Agents/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Female |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Hospitalization/sn [Statistics & Numerical Data] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Male |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Mitral Valve Insufficiency/mo [Mortality] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Quality of Life |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Severity of Illness Index |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Heart & Vascular Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Weissman, Neil J |
| 790 ## - Authors |
|---|
| All authors |
Abraham WT, Brieke A, COAPT Investigators, Cohen DJ, Grayburn PA, Kapadia SR, Kar S, Lim DS, Lindenfeld J, Mack MJ, Marx SO, Mishell JM, Rajagopal V, Rinaldi MJ, Rogers JH, Sarembock IJ, Stone GW, Weissman NJ, Whisenant BK |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1016/j.jacc.2020.12.047">https://dx.doi.org/10.1016/j.jacc.2020.12.047</a> |
| Public note |
https://dx.doi.org/10.1016/j.jacc.2020.12.047 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
